Farmas USA

Si lo se, pero donde iba es si incrementas el limite(50000€) solo tendrás que declarar las plusvalías, no?

ja.ja, estas de coña? juas,

MAS DE 50k POR LA RAZON QUE SEA DECLARAS BIENES EN EL EXTRANJERO.

luego ya el rendimiento que le saques al dinero que tengas en cualquier parte del mundo es ya son cosa de la declaracion de la renta

Perdón, quise decir si no incrementas el limite de 50000, las plusvalías generadas tributaran como tal, no?

Bien bien asi ganamos en grupo jeje. Ahora deberia quedarse por esta zona un poco mas y despues despegar. Veremos si me hace caso :)

s2 + s3.

La información de CTIX es una birria, y por eso imagino que la acción cae...
A seguir esperando...

CTIX

Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia

BEVERLY, MA--(Marketwired - June 03, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide shareholders insight to our presentation of certain clinical data at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago that concluded on Tuesday, June 2, 2015.

Cellceutix's poster provided an overview of the Company's ongoing Phase 1 clinical trial to evaluate the safety and preliminary efficacy of Kevetrin as a monotherapy (single-agent treatment) for patients with advanced solid tumors. The study has demonstrated the safety of Kevetrin administration over repeated cycles. In addition, increases in p21 expression were shown in a number of the patients in multiple cancers and p21 activity appears to be dose related. Cellceutix showed that Kevetrin may become an important therapy in the treatment of gynecological cancers/ovarian cancers.

The poster was visited by industry and academia, including key opinion leaders, representatives of large and small pharmaceutical companies, leading universities, foundations and leading international cancer scientists interested in information on Kevetrin and its ability to act upon p53, an important therapeutic target in oncology as a master regulator of the cell cycle.

Cellceutix is developing Kevetrin as a monotherapy due to its unique mechanism of action to help restore p53 function. The objective of the therapy is to trigger the natural responses of apoptosis, or programmed cell death, and cell cycle arrest. Combined with its favorable safety and pharmacokinetic profile, Kevetrin is a strong candidate not only as a potential stand-alone therapy, but also in combination with other treatments, including immunotherapies, as part of the next generation in cancer care.

THLD

Joer, verdes, a ver si arrean al 3.90 y las vendo.

PBYI

Framus, Triskis, nos suben !!

AMRN

Verdes.